Aligos.png
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 03, 2022 16:05 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos.png
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
January 26, 2022 08:00 ET | Aligos Therapeutics
Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7...
Aligos.png
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
January 11, 2022 09:12 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
Aligos.png
Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133
January 06, 2022 08:00 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos.png
Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021 16:05 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos.png
Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
December 09, 2021 08:00 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos.png
Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021
December 07, 2021 08:00 ET | Aligos Therapeutics
New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported data for HBeAg-negative patients New preclinical data...
Aligos.png
Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 08:00 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos.png
Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors
November 18, 2021 16:05 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos.png
Aligos Therapeutics to Present Virtually at the Jefferies London Healthcare Conference 2021
November 15, 2021 16:05 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...